(8-methyl-3-phenyl-nortropan-2-yl)-methanol | 50370-55-3

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: (8-methyl-3-phenyl-nortropan-2-yl)-methanol
• 英文别名: (8-methyl-3-phenyl-8-azabicyclo[3.2.1]octan-2-yl)methanol
• CAS: 50370-55-3；50372-82-2
• 化学式: C₁₅H₂₁NO
• 分子量: 231.338
• InChiKey: DAYQKDBNPICMGA-UHFFFAOYSA-N

物化性质

• 沸点：
  336.0±35.0 °C(Predicted)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Substituted amine derivatives and their use as monoamine neurotransmitter re-up-take inhibitors
  申请人：——

  公开号：US20040235906A1

  公开（公告）日：2004-11-25

  This invention relates to novel substituted amine derivatives. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

  本发明涉及新颖的取代胺衍生物。在其他方面，本发明涉及这些化合物在治疗方法中的使用，以及包括本发明化合物的制药组合物。
• SUBSTITUTED AMINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS
  申请人：NEUROSEARCH A/S

  公开号：EP1417174A2

  公开（公告）日：2004-05-12
• [EN] SUBSTITUTED AMINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS<br/>[FR] DERIVES D'AMINE SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU RECAPTAGE DES NEUROTRANSMETTEURS DE MONOAMINE
  申请人：NEUROSEARCH AS

  公开号：WO2003014114A2

  公开（公告）日：2003-02-20

  This invention relates to novel substituted amine derivatives of general formula (I) and a pharmaceutical composition comprising these compounds. In a further aspect the invention provides a method of treatment, prevention or alleviation of a disease, a disorder or a condition of a living animal body, including human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention. The diseases, disorders or conditions to be treated are especially depression, pseudodementia, Ganser’s syndrome, obsessive compulsive disorders, panic disorders, memory deficits, attention deficit hyperactivity disorder, obesity, anxiety or eating disorders.